DeirdreJillCohenMD

PubMed

• 2 citations
  Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.
  Fionnuala Crowley, Sonal Gandhi, Michelle Rudshteyn, Mantej Sehmbhi, Deirdre J Cohen> ;The Oncologist. 2023 Jun 2
• 13 citations
  Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
  Daniel J Fulop, Haley M Zylberberg, Y Linda Wu, Anne Aronson, Arielle J Labiner, Juan Wisnivesky, Deirdre J Cohen, Keith M Sigel, Aimee L Lucas> ;JAMA Network Open. 2023 Mar 1
• 1 citations
  Correction to: BTLACD200B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer.
  Brian Diskin, Salma Adam, Gustavo Sanchez Soto, Miguel Liria, Berk Aykut, Belen Sundberg, Eric Li, Joshua Leinwand, Ruonan Chen, Mirhee Kim, Ruben D Salas, Marcelo F C...> ;Oncogene. 2023 Feb 1
• 3 citations
  BTLACD200B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer.
  Brian Diskin, Salma Adam, Gustavo Sanchez Soto, Miguel Liria, Berk Aykut, Belen Sundberg, Eric Li, Joshua Leinwand, Ruonan Chen, Mirhee Kim, Ruben D Salas, Marcelo F C...> ;Oncogene. 2022 Sep 1
• 1 citations
  Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States
  Jennifer Wu, Amin Yakubov, Maher Abdul-Hay, Erica Love, Gianna Kroening, Deirdre Jill Cohen, Christy Spalink, Ankeeta Joshi, Arjun Vasant Balar, Kathie-Ann Joseph, Jos...> ;JCO Oncology Practice. 2021 Nov 8
• 11 citations
  Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
  Chengwei Peng, Deirdre Jill Cohen> ;Expert Opinion on Pharmacotherapy. 2021 Jan 2
• 63 citations
  RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.
  Wei Wang, Jill M Marinis, Allison M Beal, Shivraj Savadkar, Yue Wu, Mohammed Khan, Pardeep S Taunk, Nan Wu, Wenyu Su, Jingjing Wu, Aarif Ahsan, Emma Kurz, Ting Chen, I...> ;Cancer Cell. 2020 Oct 12
• 1 citations
  SSAT State-of-the-Art Conference: Advancements in the Microbiome.
  Miquell O. Miller, Purna C. Kashyap, Sarah Becker, Ryan M. Thomas, Richard A. Hodin, George Miller, Mautin Hundeyin, Smruti Pushalkar, Deirdre Jill Cohen, Deepak Saxen...> ;Journal of Gastrointestinal Surgery. 2021 Jul 1
• 19 citations
  Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection.
  Abhishek Pandey, Deirdre J Cohen> ;Immunotherapy. 2020 Apr 6
• 40 citations
  Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
  Gerardo A. Vitiello, Deirdre Jill Cohen, George Miller> ;Trends in Cancer. 2019 Nov 1
• 7 citations
  Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?
  Samuel Lee, Deirdre Jill Cohen> ;Expert Opinion on Pharmacotherapy. 2019 Feb 1
• 57 citations
  RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.
  Wei Wang, Jill M Marinis, Allison M Beal, Shivraj Savadkar, Yue Wu, Mohammed Khan, Pardeep S Taunk, Nan Wu, Wenyu Su, Jingjing Wu, Aarif Ahsan, Emma Kurz, Ting Chen, I...> ;Cancer Cell. 2018 Nov 12
• 2 citations
  Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation
  Salvatore Amodeo, Antonio Masi, Marcovalerio Melis, Theresa Ryan, Howard S. Hochster, Deirdre Jill Cohen, Anurag Chandra, H. Leon Pachter, Elliot Newman> ;Journal of Gastrointestinal Oncology. 2018 Oct 1
• Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following ...
  Howard S. Hochster, Paul J. Catalano, Peter J. O'Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan A. Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy,...> ;Annals of Oncology. 2018 Jun 1
• 697 citations
  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression
  Smruti Pushalkar, Mautin Hundeyin, Donnele Daley, Constantinos P. Zambirinis, Emma Kurz, Ankita Mishra, Navyatha Mohan, Berk Aykut, Mykhaylo Usyk, Luisana E. Torres, G...> ;Cancer Discovery. 2018 Apr 1
• 10 citations
  Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreat...
  Bert H. O'Neil, Aaron Scott, W. W. Ma, Steven J. Cohen, Dara L. Aisner, Alex R. Menter, Mohamedtaki Abdulaziz Tejani, Jonathan K. Cho, J. Granfortuna, Andrew L. Covele...> ;Annals of Oncology. 2016 Jun 18
• 54 citations
  Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer
  Lawrence Leichman, Susan Groshen, Bert H. O'Neil, Wells A. Messersmith, Jordan Berlin, Emily Chan, Cynthia G. Leichman, Steven J. Cohen, Deirdre Jill Cohen, Heinz-Jose...> ;The Oncologist. 2016 Feb 1
• 380 citations
  Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
  Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba, Sreenivasa Nattam, Robert de Wilton Marsh, James A. Wallace, Mark Kozloff, ...> ;Journal of Clinical Oncology. 2015 Dec 20
• 19 citations
  A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metast...
  Bert H. O'Neil, A. J. Scott, W. W. Ma, Steven J. Cohen, Lawrence Leichman, Dara L. Aisner, Alex R. Menter, Mohamedtaki Abdulaziz Tejani, Jonathan K. Cho, J. Granfortun...> ;Annals of Oncology. 2015 Dec 1
• 62 citations
  Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers
  Deirdre Jill Cohen, Lawrence Leichman> ;Journal of Clinical Oncology. 2015 Apr 27
• 399 citations
  Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
  Dung T. Le, Andrea Wang-Gillam, Vincent J. Picozzi, Tim F. Greten, Todd S. Crocenzi, Gregory M. Springett, Michael A. Morse, Herbert J. Zeh, Deirdre Jill Cohen, Robert...> ;Journal of Clinical Oncology. 2015 Apr 20
• 25 citations
  Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
  Howard S. Hochster, N. Uboha, Wells A. Messersmith, Philip J. Gold, Bert H. O'Neil, Deirdre Jill Cohen, Crystal S. Denlinger, Steven J. Cohen, C. G. Leichman, L Leichm...> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 1
• 3 citations
  Mucinous tubular and spindle cell carcinoma of the kidney: Diagnosis by fine needle aspiration and review of the literature
  Jiang Huimiao, Julie Chepovetsky, Ming Zhou, Wei Sun, Aylin Simsir, Deirdre Jill Cohen, Allen Leung> ;Cytojournal. 2015 Jan 1
• Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
  Hochster, H. S.,Uboha, N.,Messersmith, W.,Gold, P. J.,ONeil, B. H.,Cohen, D.,Denlinger, C.,Cohen, S.,Leichman, C. G.,Leichman, L.,Lenz, H. J.> ;Cancer Chemother. Pharmacol.. 2014 Dec 03
• 147 citations
  CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
  Chang Hwan Yoon, Do Joong Park, Benjamin Schmidt, Nicholas J. Thomas, Hae-June Lee, Teresa S. Kim, Yelena Y. Janjigian, Deirdre Jill Cohen, Sam S. Yoon> ;Clinical Cancer Research. 2014 Aug 1
• Join now to see all

Journal Articles

• Targeting the Hedgehog Pathway: Role in Cancer and Clinical Implications of its Inhibition  
  Cohen DJ, Hematology/Oncology Clinics of North America, 6/1/2012
• Postoperative intraperitoneal 5-fluoro-2’-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal j...  
  Cohen DJ, Newman E, Iqbal S, Chang RY, Potmesil M, Ryan T, Donahue B, Chandra A, Liu M, Utate M, Hiotis S, Pachter HL, Hochster H, Muggia F, Annals of Surgical Oncology, 2/1/2012
• Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors  
  Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS, Cancer Chemotherapy and Pharmacology, 8/1/2011
• An expert opinion on esophageal cancer therapy  
  Cohen DJ and Ajani J, Expert Opinion on Pharmacotherapy, 2/1/2011
• Treatment Paradigms with Epidermal Growth Factor Receptor-Targeted Therapies in Colorectal Cancer  
  Stein S, Cohen DJ, and Hochster H, Clinical Colorectal Cancer, 1/1/2010
• Rationale for Combining Biotherapy in the Treatment of Advanced Colon Cancer  
  Cohen DJ and Hochster H, Gastrointestinal Cancer Research, 1/1/2008
•  
  Vahdat LT, Cohen DJ, Zipin D, Lo KS, Frederick D, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS, Bone Marrow Transplantation, 8/1/2007
• Update on Clinical Data with Regimens Inhibiting Angiogenesis and Epidermal Growth Factor Receptor for Patients with Newly Diagnosed Metastatic Colorectal Caner  
  Cohen DJ and Hochster H, Clinical Colorectal Cancer, 1/1/2007
• Join now to see all

Books/Book Chapters

• New Treatment Strategies for Metastatic Colorectal Cancer 
  Chapter: Second-Line Treatment of Metastatic Colorectal Cancer: Chemotherapy with Integration of Biologic Agents- Review of Current Data. 
  Page 47 - 68Cohen DJ and Hochster HSEditors: Edward Chu.New Haven, CT2008

Abstracts/Posters

• A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.
  Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, Skoble J, Lemmens ..., J Clin Oncol, 1/1/2014
• Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (G...
  Cohen DJ, Christos PJ, Kindler HL, Catenacci DV, Bekaii-Saab T, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Take..., J Clin Oncol, 1/1/2013
• The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
  Hochster HS, Messersmith WA, O'Neil BH, Groshen SG, Lenz H, Cohen DJ, Denlinger CS, Gold PJ, Eckhardt SG, Locker GY, Ames P, McKinley M, Leichman L, Academic GI Cancer..., J Clin Oncol, 1/1/2013
• Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.
  Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, Skoble J, Lemmens ..., J Clin Oncol, 1/1/2013
• A randomized phase II study of vismodegib, a hedgehog pathway inhibitor, combined with FOLFOX in patients with advanced gastric and gastroesophageal junction carcinoma...
  Cohen DJ, Christos P, Sparano J, Kindler H, Catenacci D, Bekaii-Saab T, Tahiri S, Janjigian Y, Gibson M, Chan E, Rajdev L, Urba S, Wade J, Kozuch P, Love E, Vandris K,..., J Clin Oncol, 1/1/2012
• Mucinous neoplasms of the appendix: A single-center experience.
  Guo S, Barry M, Hajdu C, Cohen DJ, J Clin Oncol, 1/1/2012
• Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with iri...
  Hochster H, Messersmith W, O'Neil B, Groshen S, Cohen DJ, Denlinger C, Gold P, Eckhardt G, Locker G, Ames P, McKinley M, Leichman L, Academic GI Cancer Consortium, J Clin Oncol, 1/1/2012
• A randomized, double-blind-placebo-controlled phase II study of FOLFOX with or without GDC-0049 (vismodegib) in patients with advanced gastric and gastroesophageal jun...
  Cohen DJ, Liebes L, Xu R, Takebe N, Sparano JA, J Clin Oncol, 1/1/2011
• Quantitative expression of the hedgehog (Hh) signaling pathway in gastric carcinoma: A novel protocol to process RNA from paraffin-embedded tissue.
  Akalu A., Liebes L, Xu R, Schneider R, Takebe N, Cohen DJ, American Association for Cancer Research (AACR) Symposium, 1/1/2011
• Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
  Cohen DJ, Leichman LP, Love E, Ryan T, Leichman GC, Newman E, Levinson B, Hochster H, Journal of Clinical Oncology 2011 Gastrointestinal Cancers Symposium, 1/1/2011
• A Phase I/II Study of induction oxaliplatin and 5FU chemo-radiation.
  Melis M, Ryan T, Hochster H, Cohen DJ, Masi A, Chandra A, Pachter HL, Newman E, Digestive Disease Week, 1/1/2011
• Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation.
  Ma H, Yuan Y, Ryan T, Newman E, Cohen DJ, Choi H, Hochster HS, ASCO Gastrointestinal Cancers Symposium, 1/1/2009
• Activity and tolerance of biweekly CapeOx-Cetuximab in first-line therapy of metastatic colorectal cancer (mCRC) and K-ras influences.
  Yuan Y, Ma H, Cohen DJ, Ryan T, Choi H, Love E, Awad M, Khambata-Ford S, Mauro D, Hochster HS, ASCO Gastrointestinal Cancers Symposium, 1/1/2009
• Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): Preliminary results on toxicity and K-r...
  Cohen DJ, Ma H., Yuan Y., Hochman T., Hochster HS, Journal of Clinical Oncology, 2008 Annual Meeting Proceedings Part I, 5/20/2008
• Intraperitoneal(IP) 5'-fluoro-2'deoxyuridine(FUDR): Safety and outcome when administered prior to adjuvant chemoradiotherapy(chemoRT) following R0 resection for gastri...
  Cohen DJ, Ryan T, Newman E, Iqbal S, Liu M, Utate M, Moore S, Potmesil M, Hochster H, Muggia FM, Journal of Clinical Oncology, 2007 Annual Meeting Proceedings Part I, 6/20/2007
• Intraperitoneal (IP) 5’-fluoro-2’-deoxyuridine (FUDR): Safety and outcome when administered prior to standard adjuvant chemoradiotherapy (chemoRT) following R0 surgica...
  Cohen DJ, Newman E, Iqbal S, El-Khoueiry S, Hiotis S, Marcus S, Ryan T, Liu M, Chandra A, Muggia F, ASCO Gastrointestinal Cancers Symposium, 1/1/2007
• Randomized trial of low-dose interleukin-2 vs. cyclosporine A and interferon-Gamma after high dose chemotherapy with peripheral blood progenitor support in women with ...
  Cohen DJ, Vahdat LT, Zipin D, Lo KS, Frederick D, Donovan D, Sharpe E, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS, 27th Annual San Antonio Breast Cancer Symposium, 1/1/2004
• Join now to see all

Lectures

• A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors. 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic ... 
  2019 ASCO Annual Meeting - 6/1/2019
• “Multidisciplinary Management of Localized Gastroesophageal Junction Cancers” 
  1/16/2014
• “A Randomized Phase II Study of Vismodegib (GDC-0449), a hedgehog pathway inhibitor, combined with FOLFOX in patients with advanced gastric and gastroesophageal juncti... 
  Bethesda, MD - 10/15/2012
• “Targeting the Hedgehog Pathway: Role in Gastroesophageal Cancer and Clinical Implications of its Inhibition” 
  Marriott Marquis, NYC - 11/9/2011
• “Progress in Therapy of Advanced Colorectal Cancer." 
  3/9/2011
• “P8376: Randomized Phase II Trial of FOLFOX6 +/- GDC-0449 in Gastric and GE Junction Cancer.” 
  NYC - 5/14/2010
• “Chemotherapy for Advanced Gastric Cancer." 
  New York University Medical Center - 4/22/2010
• “Colorectal Cancer” Advanced Immunology: the Gastrointestinal System 
  3/30/2010
• “The Hedgehog Pathway: Rationale for its inhibition in GI Cancers.” 
  12/7/2009
• “Pancreatic Cancer: Medical Management of Early Stage Disease." 
  New York University School of Medicine - 12/3/2009
• "The Hedgehog Pathway: Rationale for its inhibition in GI cancers.” 
  Marriott Marquis, NYC - 11/11/2009
• “Updates from ASCO Program 2009.” 
  6/10/2009
• “Progress in Therapy of Advanced Pancreatic Cancer.” 
  5/19/2009
• Join now to see all